Australia markets closed

Santhera Pharmaceuticals Holding AG (SPHDF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
11.700.00 (0.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.70
Bid0.00 x 0
Ask0.00 x 0
Day's range11.70 - 11.70
52-week range0.68 - 13.35
Avg. volume9
Market cap132.44M
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-9.50
Earnings date05 Sept 2024 - 09 Sept 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

    Pratteln, Switzerland, June 18, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 4,535,785 shares or 35.9% of the Company’s share capital. Approval of the 2023 Annual Report and discharge of corporate bodiesThe shareholders approved the Annual Report, the annual financial stateme

  • GlobeNewswire

    Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even

    Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on June 19, 2024, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release. Funding underpins the advancement of AGAMREE® (vamorolone) roll-out and growth in Europe and the pursuit of further developmental initiatives Financing includes up to USD 38 million from R-Bridge, an affiliate of CBC Group, in exchange for a partial monetization of royalty payments received by Santhera in North America and

  • GlobeNewswire

    Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix

    Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE® (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD). In April 2024, the Hainan Medical Products Administration (HMPA) authorized the EAP for AGAMREE based on local policies, AGAMREE’s existing overseas approvals (U.S., EU, UK) and its demonstrated ability to address urgent clinical need